



US 20210299094A1

(19) **United States**(12) **Patent Application Publication**  
LIN et al.(10) **Pub. No.: US 2021/0299094 A1**(43) **Pub. Date: Sep. 30, 2021**(54) **METHODS OF UPREGULATING TIPARP AS  
ANTICANCER STRATEGIES***A61P 35/00* (2006.01)*A61K 31/05* (2006.01)(71) Applicant: **CORNELL UNIVERSITY**, Ithaca, NY  
(US)(52) **U.S. Cl.**CPC ..... *A61K 31/404* (2013.01); *A61K 31/138*  
(2013.01); *A61K 31/05* (2013.01); *A61K*  
*31/357* (2013.01); *A61P 35/00* (2018.01);  
*A61K 31/352* (2013.01)(72) Inventors: **Hening LIN**, Ithaca, NY (US); **Lu**  
**ZHANG**, Ithaca, NY (US)(21) Appl. No.: **17/260,124**(57) **ABSTRACT**(22) PCT Filed: **Jul. 24, 2019**(86) PCT No.: **PCT/US2019/043206**

§ 371 (c)(1),

(2) Date: **Jan. 13, 2021****Related U.S. Application Data**(60) Provisional application No. 62/702,634, filed on Jul.  
24, 2018.**Publication Classification**(51) **Int. Cl.***A61K 31/404* (2006.01)*A61K 31/138* (2006.01)*A61K 31/352* (2006.01)*A61K 31/357* (2006.01)

The present disclosure is directed to a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a TipARP agonist, wherein the TipARP agonist may be, for example, a tamoxifen compound (e.g., tamoxifen or derivative thereof), flavone or derivative thereof, isoflavone or derivative thereof, diindolylmethane compound, or chlorinated dibenzo-p-dioxin (CDBD) compound or derivative thereof. The cancer may be associated with elevated expression of HIF-1 $\alpha$  and may be selected from, for example, breast cancer, colon cancer, lung cancer, skin cancer, brain cancer, blood cancer, cervical cancer, liver cancer, prostate carcinoma, pancreas carcinoma, gastric carcinoma, ovarian carcinoma, renal cell carcinoma, mesothelioma, and melanoma. The cancer may, in some embodiments, exclude breast cancer.

**Specification includes a Sequence Listing.**